Long-term safety follow-up for luspatercept study participants
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older when you sign consent.
- You must have already participated in a luspatercept study, and be eligible to continue based on the original study plan (luspatercept, placebo crossover, or follow-up rollover).
- You must agree to follow the study visit schedule and study rules, and you must be compliant with the original study requirements.
- You must be willing to sign consent before any study procedures happen.
- If you are a person who could become pregnant: you need 2 negative pregnancy tests before starting and ongoing pregnancy testing, plus reliable birth control for the required time window.
- If you are male: you must agree to use a condom with a pregnant partner or a partner who could become pregnant during the study and for 84 days after stopping the study medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
This study is checking the safety of a drug called Luspatercept (brand name Reblozyl) for people in Korea who have myelodysplastic syndrome (a blood disorder) or beta-thalassemia (a type of inherited anemia). It is designed to monitor how safe the drug is when used as prescribed by your doctor.
This study looks at how well a medication called Luspatercept works for adults with transfusion-dependent beta-thalassemia, a blood condition that requires regular blood transfusions. Researchers want to understand how it helps people in the Middle East.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This trial tests a drug called luspatercept (Reblozyl) as the first treatment for people with a bone marrow disorder that causes low blood counts and requires regular blood transfusions. The drug may help reduce the need for transfusions by improving red blood cell production.
This study tests a drug called luspatercept for people with a mild form of aplastic anemia who still need frequent blood transfusions. Luspatercept may help your body make more red blood cells, reducing the need for transfusions and improving your energy.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.